In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fujisawa Healthcare and Roche co-promote Mycamine in the US

Executive Summary

Fujisawa Healthcare and Roche's pharmaceutical division will co-promote Fujisawa's antifungal Mycamine (micafungin) injection, which was just approved by the FDA to treat esophageal candidiasis and as a Candida infection prophylaxis in patients undergoing hematopoietic stem cell transplantation (HSCT).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies